Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Liu

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature|February 25, 2000
Debating controversies can enhance creativityS V Liu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2019
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forwardC Kim, S V Liu
Journal of Clinical Pharmacy and Therapeutics|March 22, 2012
Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumabS V Liu, R Gollard, S Iqbal
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutationsS V Liu, X Hu, D Chirovsky, et al.
ESMO Open|January 6, 2026
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE studyS Peters, R J-B Salomonsen, I Diaz Perez, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2021
Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)K A Higgins, W J Curran, S V Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2025
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitorsS V Liu, R Dziadziuszko, S Viteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialA S Mansfield, A Każarnowicz, N Karaseva, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature|February 25, 2000
Debating controversies can enhance creativityS V Liu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2019
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forwardC Kim, S V Liu
Journal of Clinical Pharmacy and Therapeutics|March 22, 2012
Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumabS V Liu, R Gollard, S Iqbal
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutationsS V Liu, X Hu, D Chirovsky, et al.
ESMO Open|January 6, 2026
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE studyS Peters, R J-B Salomonsen, I Diaz Perez, et al.
International Journal of Radiation Oncology, Biology, Physics|January 11, 2021
Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)K A Higgins, W J Curran, S V Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2025
ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitorsS V Liu, R Dziadziuszko, S Viteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2020
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsJ Laskin, S V Liu, K Tolba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialA S Mansfield, A Każarnowicz, N Karaseva, et al.
Pageof 2